by Raynovich Rod | Aug 13, 2013 | Biopharmaceuticals
Market Can’t Stay Down in Quiet Trading After a couple of lackluster trading days the market perked up as economic news continues positive with retail sales up for the fourth consecutive month and many analysts believing Europe is coming out of recession. And...
by Raynovich Rod | Aug 8, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
Intrexon (XON), a synthetic biology Company, focused in healthcare, animal science and agriculture raised over $160M in a Huge IPO . CEO Randall Kirk purchased 30M shares. Some pundits say this event punctuates the “golden age of biology”. This is the...
by Raynovich Rod | Aug 6, 2013 | Biopharmaceuticals
Weakness in NASDAQ and Earnings Miss Gives an Excuse To Sell The Blistering 14% July Run in Biotech Comes to an End It was inevitable that something would cause biopharmaceutical stocks to falter. Today it was overall weakness in the market and a miss by the highest...
by Raynovich Rod | Aug 1, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Biotech ETF (IBB) Hits New High of $200-Mid Caps Get Turbo Boost Positive Economic Data Helps The life science sector roared ahead again today helped by a 1% move in NASDAQ now at YTD highs up 21%. With an earlier post last week we urged “staying the...
by Raynovich Rod | Jul 23, 2013 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
Rayno Life Science: Mid-Day Movers – IBB down 0.9% UP Diagnostics and Tools: Cepheid (CPHD) up 2.55%.Hologic (HOLX) up 3.7%, Response Genetics (RGDX) up 3.2% Biopharmaceuticals: Array (ARRY) up 12.7%, Astex (ASTX) up 2.2%, Viropharma (VPHM) up 1.12% DOWN...
by Raynovich Rod | Jul 18, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
7/19 11:45a EDT Update -Correction Limited to Techs, Biotechs Surge Tech correction continues with XLK down 1.5% but more money finding its way into biotech “bubblet” with IBB ($195) up 1.6%.Leading sectors are energy, healthcare and industrial with...
by Raynovich Rod | Jul 16, 2013 | Biopharmaceuticals
Biotech Stocks Take A Breather: NASDAQ off 0.3% at 3597 A little profit taking has set in after it seemed that the market would roar all summer. From the action in mid-cap biopharma stocks it looks like hedge funds are taking some off among high flyers.NASDAQ has been...
by Raynovich Rod | Jul 11, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
Strong NASDAQ Up 1.35%-IBB Hits 188.82 All Time High A stealth rally that began with futures after the close yesterday was triggered by Bernanke comments interpreted by the market as backtracking on “tapering”. Maybe Bernanke was trying to soften his...
by Raynovich Rod | Jul 10, 2013 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
Rayno Life Science Movers 2% or more Alexion (ALXN $97.8) up 2.14% Amgen (AMGN $100.71) up 2.4% Pharmacyclics (PCYC $100.55) up 12% Vermillion (VRML $2.90) up 10.6% After a 4 day S&P rally up 2.7% stocks are taking a rest but the IBB ($183.56) rallied another...
by Raynovich Rod | Jul 8, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Stocks Are Mixed-Biopharma Weak But Diagnostics Strong The life science sector traded along with NASDAQ today so as the NAZ sold off (tech stock weakness) biotech followed. The IBB (181.51) off 0.58% could not regain momentum as of mid-day trading after a...